
PRESCIENT / AMP SCZ
The PRESCIENT project, part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, focuses on predicting clinical outcomes in individuals at clinical high risk (CHR) for psychosis.
Research theme
Machine-learning models that forecast individual outcomes in people at clinical high risk.

The PRESCIENT project, part of the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, focuses on predicting clinical outcomes in individuals at clinical high risk (CHR) for psychosis.

The CARE study, part of the CARE Network (Computer-assisted Risk Evaluation), is an innovative clinical research project aimed at early detection and prevention of psychosis.

A focus of our lab is the identification of individuals that are at-risk to develop a psychiatric disorder.

Cognitive symptoms are a central feature of most psychiatric diseases including psychotic and affective disorders. Recent results, including work from our lab (Kambeitz-Ilankovic et al., 2019), demonstrated that cognitive training can effectively improve cognitive performance in patients with psychosis.
Acta Psychiatr Scand · 2026
Schizophr Res 293, 99–108 · 2026
Transl Psychiatry · 2026
Schizophr Bull 52 · 2026
BMJ Ment Health 29 · 2026